JMA Exec. Mikami Wants a Hold on Info Disclosures Based on Transparency Guidelines

Pharmaceutical companies should postpone their plans, beginning in FY2013, to disclose their payments to healthcare professionals based on the Japan Pharmaceutical Manufacturers Association’s (JPMA) transparency guidelines, Hiroshi Mikami, an executive board member of the Japan Medical Association (JMA), told Jiho...read more